MediciNova, Inc. (MNOV) Financial Statements (2024 and earlier)

Company Profile

Business Address 4275 EXECUTIVE SQUARE
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments58,48871,43160,03763,79362,31327,992
Cash and cash equivalents18,50571,43160,03763,79362,31327,992
Short-term investments 39,982     
Receivables      
Other undisclosed current assets499578680512445337
Total current assets:58,98772,00960,71764,30562,75828,328
Noncurrent Assets
Operating lease, right-of-use asset629824 400
Property, plant and equipment455856415363
Long-term investments and receivables      617
Long-term investments      617
Intangible assets, net (including goodwill)9,6009,6009,6009,6009,6009,600
Goodwill9,6009,6009,6009,6009,6009,600
Other noncurrent assets931152464601111
Other undisclosed noncurrent assets4,8004,8004,8004,4004,8004,800
Total noncurrent assets:15,16815,39814,70214,90114,46415,091
TOTAL ASSETS:74,15587,40675,41979,20577,22343,419
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,5681,6251,7921,6552,1922,881
Employee-related liabilities636823768  
Accounts payable4254036174516171,520
Accrued liabilities 1,1435853524361,5751,361
Debt    217  
Other undisclosed current liabilities1,6201,208402356  
Total current liabilities:3,1872,8332,1942,2282,1922,881
Noncurrent Liabilities
Long-term debt and lease obligation:    183  
Liabilities, other than long-term debt7258961,8991,8812291,896
Deferred revenue and credits1,694
Deferred revenue   1,6941,694
Deferred rent credit     27
Deferred tax liabilities, net202202
Deferred income tax liabilities202202202 
Other liabilities5246953186  
Operating lease, liability    183
Other undisclosed noncurrent liabilities    191,694 
Total noncurrent liabilities:7258961,8992,0821,9231,896
Total liabilities:3,9133,7294,0934,3114,1154,777
Equity
Equity, attributable to parent70,24283,67771,32774,89573,10838,642
Common stock494945444236
Additional paid in capital477,438476,788454,297444,016429,290380,157
Accumulated other comprehensive loss(115)(99)(88)(93)(93)(95)
Accumulated deficit(407,130)(393,061)(382,927)(369,073)(356,131)(341,456)
Total equity:70,24283,67771,32774,89573,10838,642
TOTAL LIABILITIES AND EQUITY:74,15587,40675,41979,20577,22343,419

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues 4,038    
Cost of revenue
(Cost of Goods and Services Sold)
      (300)
Gross profit: 4,038   (300)
Operating expenses(14,629)(14,253)(14,178)(14,031)(15,587)(13,027)
Other undisclosed operating income      300
Operating loss:(14,629)(10,216)(14,178)(14,031)(15,587)(13,027)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(247)(59)(38)(46)(23)120
Interest and debt expense      (0)
Other undisclosed income from continuing operations before equity method investments, income taxes     940 
Loss from continuing operations before equity method investments, income taxes:(14,876)(10,275)(14,217)(14,077)(14,670)(12,907)
Income (loss) from equity method investments     20(2)
Other undisclosed income (loss) from continuing operations before income taxes8101443611,148(20)2
Loss from continuing operations before income taxes:(14,066)(10,132)(13,856)(12,929)(14,670)(12,907)
Income tax expense (benefit) (3)(3)2(13)(5)1,744
Other undisclosed loss from continuing operations      
Loss from continuing operations:(14,069)(10,134)(13,854)(12,942)(14,675)(11,163)
Loss before gain (loss) on sale of properties:(10,134)(13,854)(12,942)(14,675)(11,163)
Other undisclosed net income      
Net loss:(14,069)(10,134)(13,854)(12,942)(14,675)(11,163)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(14,069)(10,134)(13,854)(12,942)(14,675)(11,163)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(14,069)(10,134)(13,854)(12,942)(14,675)(11,163)
Comprehensive loss:(14,069)(10,134)(13,854)(12,942)(14,675)(11,163)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(16)(11)4011
Comprehensive loss, net of tax, attributable to parent:(14,085)(10,145)(13,849)(12,941)(14,674)(11,162)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: